Metformin or did not improve over the adolescent patients with severe type 1 diabetes

A study published in the international journal JAMA research papers, scientists from the Jaeb Health Research Center conducted a clinical trial, including the risk of type 1 diabetes in overweight and obese adolescents study found that metformin added to insulin in perhaps six months later and the situation does not improve glycemic control in patients.
For adolescents with type 1 diabetes, overweight or obese can potentially lead to severe metabolic disorders, especially in the period of adolescence; in adolescents in the study, a high dose of insulin can overcome obesity, insulin resistance, at the same time also trigger puberty individual blood glucose control difficult, but the future lead to weight gain individual; and Metformin is an oral hypoglycemic agents, commonly used to treat type 2 diabetes mellitus; metformin on previous studies assessed adolescents with type 1 diabetes blood glucose control , but did not get the results uncertain.
The researchers randomly assigned Dr. Kellee M. Miller in the article of 140 aged 12-19 years old adolescents with type 1 diabetes with metformin or placebo treatment period of 6 months, individuals with diabetes is at least seven years, and receiving metformin The dose of 2000mg / d or more, the trial while 26 pediatric endocrinology diagnostics; researchers found that although 13 weeks of metformin group of individuals body glycated hemoglobin